Inogen Announces CFO Transition Plan
December 13 2021 - 6:00AM
Business Wire
– Names Mike Sergesketter as Interim Chief
Financial Officer –
Inogen, Inc. (NASDAQ: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced the appointment of Mike Sergesketter as
Interim Chief Financial Officer, effective immediately. Mr.
Sergesketter most recently served as CFO of Kimball Electronics,
Inc. where he was instrumental in helping to develop and execute
the company’s globalization strategy while also building a robust
finance function designed to support the company’s growth. He
succeeds Alison Bauerlein who will be staying with the Company in a
transitional finance role through the first quarter of 2022. The
Company has retained a leading executive search firm to help with
the search for a permanent replacement.
Nabil Shabshab, President and Chief Executive Officer of Inogen,
said, “The changes we have made to our executive team support our
continued strategic evolution and our goal of transforming Inogen
into a more prominent player in respiratory care. I’m confident
Mike’s strong experience in finance, strategic manufacturing and
M&A, as well as his global perspective, will be a tremendous
asset as we continue to execute against our plans. I am grateful
for the time and collaboration I have had with Ali and want to
thank her for her many contributions as a key member of the team
that launched and grew Inogen. I wish her well in her future
endeavors.”
Ms. Bauerlein added, “It has been an honor to work with such an
exceptional and committed team over the past 20 years to help
improve the lives of patients worldwide. As part of Inogen’s
founding team, I am proud of our innovative and market-leading
product portfolio, and I look forward to following Inogen’s
continued evolution and success.”
Mike Sergesketter Biography
Mr. Sergesketter brings over forty years of finance experience
in the manufacturing services industry. He brings expertise working
across business functions, including with the CEO and Board of
Directors, Audit Committee and Compensation and Governance
Committee. As part of his role as the CFO of Kimball Electronics,
Inc. following its spin-off in 2014 and through June 2021, Mr.
Sergesketter led the transformation of the finance and reporting
functions to support the newly formed public company, helping to
formulate and execute on the strategy that led to global expansion.
During his tenure at Kimball Electronics and its predecessors, Mr.
Sergesketter had the responsibility for a number of critical
finance functions, including SEC reporting, Treasury, Investor
Relations, Tax, Financial Planning & Analysis, Internal Audit
while playing a leading role in various M&A transactions in the
US and abroad.
About Inogen
We are a medical technology company offering innovative
respiratory products for use in the homecare setting. We primarily
develop, manufacture and market innovative portable oxygen
concentrators used to deliver supplemental long-term oxygen therapy
to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements with respect to the
announced management and organizational changes, statements
concerning or implying Inogen’s future financial performance,
trends and opportunities affecting Inogen, and the ability of
management personnel to contribute to the execution of Inogen’s
strategic plans and goals to expand, grow, and transform its
business. Any statements contained in this communication that are
not statements of historical fact may be deemed to be
forward-looking statements. Words such as “believes,”
“anticipates,” “plans,” “expects,” “will,” “intends,” “potential,”
“possible,” and similar expressions are intended to identify
forward-looking statements. Forward-looking statements are subject
to numerous risks and uncertainties that could cause actual results
to differ materially from currently anticipated results, including
but not limited to, risks related to its announced management and
organizational changes, and risks arising from the possibility that
Inogen will not realize anticipated future financial performance or
strategic goals. In addition, Inogen's business is subject to
numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of its products;
competition; its sales, marketing and distribution capabilities;
its planned sales, marketing, and research and development
activities; interruptions or delays in the supply of components or
materials for, or manufacturing of, its products; seasonal
variations; unanticipated increases in costs or expenses; and risks
associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
Inogen’s business operating results are contained in its Quarterly
Report on Form 10-Q for the period ended September 30, 2021, and in
its other filings with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof.
Inogen disclaims any obligation to update these forward-looking
statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211213005205/en/
Investor and Media Contacts Bryan Locke, Mike DeGraff,
Gabriella Coffey Inogen-SVC@sardverb.com (312) 895-4700
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Apr 2023 to Apr 2024